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S U M M A R Y
The studies described in this thesis focus on cortisol metabolism, and in particular
on the act iv i ty of  11B-hydroxysteroid dehydrogenase (11BHSD), and their
contribution to the pathogenesis of several clinical conditions, characterized by
abnormalities in volume or glucose homeostasis.
Chapter L contains a general overview on cortisol metabolism and 11BHSD
activity. The intracellular enzyme 11pHSD catalyses the interconversion between
the hormonally active cortisol and inactive cortisone. In humans, two isozymes
exist, designated as 11BHSD type 1 and 11BHSD type 2. ln aiao, 11PHSD type 1
behaves as a NADPH-dependent reductase, thus activating cortisone towards
cortisol. 11pHSD type2 functions as a NAD.-dependent dehydrogenase, thereby
inactivating cortisol into cortisone. In addition to differences in catalytic activity,
these two isozymes also have a different tissue distribution pattern. 11BHSD type
1 is ubiquitously expressed, but is notably absent in human kidney. In contrast,
expression of 11BHSD type 2 is more limited to the mineralocorticoid target organs
(i.e. kidney, colon, salivary glands) and placental tissue. The 11BHSD isozymes
can be regarded as molecular switches, regulating the bioavailability of cortisol
for binding to its receptor. Besides activating the glucocorticoid receptor, cortisol
also has the ability to activate the mineralocorticoid receptor, which binds cortisol
wi th the same aff in i ty as aldosterone in ai t ro.  ln aiao, st imulat ion of  the
mineralocorticoid receptor by cortisol is prevented by the cortisol inactivating
effect  of  11BHSD type 2.  Thus, 11BHSD type 2 confers speci f ic i ty to the
mineralocorticoid receptor in the presence of glucocorticoids. The activity of
11PHSD in aiao is usually assessed by measurement of the ratios of plasma
cortisol/cortisone and urinary (THF + allo-THF) /THE, reflecting the overall index
of 11BHSD activity. In addition, the UFF/UFE ratio has been proposed to reflect
more specifically the activity of 11BHSD type 2 in kidney. The impact of 11ÊHSD
in several clinical conditions, such as AME syndrome, liquorice abuse, hypertension,
diabetes mellitus and obesity, is discussed.
Chapter 2 describes the effect of acute administration of angiotensin on 11BHSD
activity. We examined 21 male healthy subjects after 1 week of a low- and high-
salt diet. Separate infusions of angiotensin-I and II were administered, both at
two different doses. Glomerular filtration rate was accurately measured, in order
to adjust for angiotensin-mediated changes in renal function.
Angiotensin-I and II infusion dose-dependently increased mean arterial blood
pressure and plasma aldosterone, and decreased plasma renin activity and glomerular
filtration rate at both diets. During angiotensin-I and II infusion, we observed a



































































at both diets, without any change in the urinary (THF+allo-THF) /Tï{E ratio. Salt
restriction did not affect these 11BHSD parameters, but was accompanied by u
decrease in UFF and UFE excretion.
These data suggest that acute angiotensin administration stirnulates the
activity of 11BHSD type 2 in human kidney. We therefore hypothesize that
angiotensin exerts a dual effect on the mineralocorticoid receptor, i.e. an indirect
agonistic effect by increasing aldosterone availability and a direct or indirect
antagonistic effect by stimulation of renal 11BHSD type 2 activity resulting in a
decreased cortisol-mediated receptor activation. The observed effect of dietary
salt intake on UFF and UFE excretion is most l ikely due to sodium-induced
alterations in cortisol elimination, as further described in chapter 4.
Chapter 3 addresses the question whether an altered setpoint of the 11PHSD
mediated cortisol to cortisone interconversion towards cortisol is pathogenetically
involved in the sodium retention of patients with the nephrotic syndrome.
Therefore, we studied the serum cortisol/cortisone ratio and the ratios of urinary
(THF+allo-THF) /TF{E and of IJFF / UFE in B proteintrric patients and in B matched
healthy subjects. In addition, the effect of angiotensin-Il receptor blockade on
11BHSD activity was evaluated, by placebo-controlled administration of losartan
50 mg/day dur ing 4 weeks.
There were no significant differences betr,r'een proteinuric patients and healthy
subjects in serum cortisol, serum cortisone, serum cortisol to cortisone ratio, or in
the urinary excretions of THF, allo-THF, THE, sum of cortisol metabolites or
(T'HF+allo-THF) /T}{E ratio. UFF excretion and the UFF/UFE ratio were lovver
in proteinuric patients than in healthy subjects. Losartan treatment resulted in
significant reduction of mean arterial pressure and proteinuria, but did not affect
cor t i so l  metabo l ism.
In contrast to previous studies, our data suggest an increased renal inactivation
of cortisol in proteinuric patients. Thus , this study does not suprport the contention
that an altered 11BHSD activity contributes to sodium retention in patients with
the nephrotic syndrclme. Moreover, although a relatively low dose of losartan
recluces rnean arterial pressure and proteinuria, it does not exert a significant
effect on the cortisol to cortisone interconversion.
Chapter 4 is directed at the question whether the sodium-dependency of blood
pressure (i.c. salt sensitivity) is l inked with changes in cortisol metabolism. As
previous studies have suggested that salt loading can affect insulin sensitivity,
we also examined whether changes in insulin sensitivity after salt loading are
associated r.t,ith alterations in cortisol metabolisrn. Therefore, we studied cortisol
metabolism and insulin sensitivity in 28 healthy normotensive subjects after a
lor,r '- and high-salt diet. Based on their blood pressure response to salt loadirrg, 19
subjects were classified as salt-resistant and 9 subjects as salt-sensitive.
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Interestingly, we found that the sum of urinary cortisoi metabolite excretion after
salt loading increased in salt-resistant and decreased in salt-sensitive subjects.
This was accompanied by a clecrease in morning plasma cortisol levels in salt-
resistant subjects, which did not change significantly in salt-sensitive subjects.
Moreot'er, changes in cortisol metabolite excretion after salt loading were inversely
related to changes iu plasma morning cortisol. The most l ikely explanation of
these observations is that salt loading increases cortisol elimination rate in salt-
resistant subjects, a response which is blunted in salt-sensitive individuals. We
suggest that this variation in cortisol elimination is probably caused by sodium-
irrduced alterations in l iver hemodynamics, as has been demonstrated previously
bv others. Although liver hemodynamics were not studied, we did observe that a
sc-rditrm-indtrced ecrease in blood pressure was accompanied by an increase in
renal r.a-rsodilatatiou. A similar hemodynamic response in the l iver is expected to
result in enhancement of cortisol elimination. Indeed, we did find that an increase
in renal vascldilatation was accompanied bv an increase in the sum of urinary
cortisol metabolites. Although ir-rsulin sensitivity, as determined by horneostatic
mociel assessment (HOMA), did not change sigrrificantly in either group, analysis
of all subjects together revealed that a rise in insulin resistance was associated
with an increase in plasma morning cortisol and a decrease in the sum of urinarv
cortisol metabolites excreted. Salt-resistant and salt-sensitive subjects demonstrated
similar activit ies of 11BHSD, which was not affected by variation in dietary salt
intake.
We conclude that salt loading increases cortisol elimination in salt-resistant
normotensive subjects, a response which is blunted in salt-sensitive subjects. In
addition, changes iu circtrlating cortisol might explain individual variations in
insulin sensitir, ' i ty in response to alterations in dietarv sodium intake.
Chapter 5 is aimed at evaluating cortisol production and tlre 11BHSD activity in
type 1 cliabetic patients. As several previor,rs studies might have been confounded
by gender distribution and differences in body mass index and dietary'sodium
intake, n,e studied cortisol metabolism durir-rg a low- and high-salt diet in 14
m a l e ,  n o n o b e s e ,  n o r n l o t e n s i v e  t y p e  1  d i a b e t i c  p a t i e n t s  l v i t h o u t  s e v e r e
cornpl icat ions and a HbA1. less than 8.5 ' ) i ,  and in 14 indiv idual lv matched heal thy
sub jec ts .
We found that the sum of urinary cortisol metabolite excretion during both
diets n,as significantly lower in diabetic patients than in healthy subjects. In
addition, the allo-THF excretion and allo-TFIF/THF ratic-r were lower in diabetic
tharn in healthv males during both diets. The ratios of urinarv (THF+alloTHF) /TIHE
arrd UFF/UFE were simi lar  in both groups and remained unchanged af ter  sal t
lc-rading.
Thtrs, the sum of urinary cortisc-ri metabolite excretion as a measllre of cortisol
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adequate glycaemic control and r,l, i thout severe complications, irrespective of
sodium intake. This might in part be explained by a diminished 5tx reductase
activity, resulting in a decreased cortisol metabolic clearance. Moreover, there is
no difference in 11BHSD setpoint between type 1 diabetic and in healthy males,
and this setpoint is not affected by physiological variations in sodium irrtake.
Chapter 6 evaluates the relationship between insulin resistance and 11BHSD
activity irr type 2 diabetes mellitus. To this end, the urinary (THF+allo-THF)/THE
and UFF / IJFE rat ios,  as wel l  as the pr lasma cc-rr t isol /cort isone rat io were
measttrecl in B male type 2 diabetic patients trnd B healthy male subjects w,ithout
and after 24h of insulin infused at a rate of 30 mlJ /kg/h to achieve moderate
hyperinsulinaemia. Insulin was infused in the expectation that this would lower
insulin sensitivity. Insulin sensitivity was assessed by measurement of whole body
glucose uptake during a euglycaemic clamp (insulin infused at 30 mU/kg/h)
directly after the 24h insulin infr,rsion and on a control day.
Baseline urinary (THF+allo-THF) /TF{E and plasma cortisol/cortisone at
0800h were similar in type 2 diabetic patients and healthy subjects, despite an
impaired insulin sensitivity in the former group. Moreover, no correlation could
be demonstrated between insulin sensitivity and baseline urinary (THF+allo-THF)/
THE and plasma cortisol/cortisone. In typ-re 2 diabetic patients, insulin sensitivity
was further impaired by antecedent hyperinsulinaemia, but this impairment
r,r 'as not accompanied by changes in urinary (THF+allo-THF)/THE or irr plasma
cortisol/cortisone at 0800h. In healthy subjects, insulin sensitivity did not change
sigrr i f icant ly af ter  24 h i r rsul in infusion, despi te an increase in both ur inarv
(THF+ailo-THF)/THE and plasma cortisol/cortisone. The UFF /UFE ratio was
r ro t  d i f fe ren t  be tween the  two groups  and was no t  a f fec ted  by  insu l in
administration.
In conclusion, th is study does not support  the hypothesis that  instr l in
resistance in type 2 diabetes mellitus is associated with an overall change in the
l1BHSD setpoint towards cortisol. The observed stimulation of 11BHSD reductase.
activity by insulin, as inferred from the increase in the urinary (THF+allo-THF)/
THE ar-rd plasma cortisol,/cortisone ratios, could further contribute to visceral
obesity, in vier.t, of the stirnulatory effects of irrsulin and cortiscll on adipclgenesis.
Chapter 7 focuses on recombinant human grolt,th horrnone (rhGll) replacement
and its possible influence on the activity of 11PHSD and on the bioavailabil ity of
cort isone acetate tablets.  A 12-month randomised, placebo-control led rhGH
replacement study was conducted. TWelve men and 12 women r.t,ith GH deficiencv
of r.t,hom 17 received cortisone acetate participated.
No changes in urinary cortisol metabolites were observed after placebo. After
6 months rhGH the urinary (THF+allo-THF) /TF{E ratio was unaltered in cortisone
acetate treated patients as well as in patients with intact adrerral function, whereas
1 3 5
after 12 months rhGH the (THF + al lo-THF)/TUP rat io decreased only in
cortisone acetate treated patients. The sum of urinary cortisol metabolites did
not change after rhGH in either group. The UFF /UFE ratio tended to decrease
in cortisone acetate treated as well as in patients with intact adrenal function.
Thus, it is suggested that 11BHSD type 1 activity is decreased by rhGH
replacement, which becomes manifest in patients receiving cortisone acetate
substitution therapy. 11BHSD type 2activity is unaltered or may even be increased.
The bioavailabil ity of conventional doses cortisone acetate is unlikely to be
impairecl by rhGFI replacement in hypopituitary patients.
Chapter 8 descr ibes a new assay, based on gas chromatography and mass
spectrometry, to detect low concentrations of 1BB-glycyrrhetinic acid (1BBGA) in
urine, the hydrolytic product of glycyrrhizin. lBBGA inhibits the dehydrogenase
erctivity of 11BHSD, and is therefore responsible for the mineralocorticoid side-
effects of l iquorice.
The detection limit for 1BBCA of the gas chromatography assay was 10 ttg/1,
which was further lowered to 3 ytg/l by subsequent mass spectrometry. The
performance of this newly developed assay is demonstratecl in a group of four
volunteers consuming clifferent amounts of liquorice.In addition, its clinical value
is illustrated in two patients with hypokalaemic hypertension and suppressed
plasma renin activity and aldosterone, in whom a suspicion of l iquorice abuse
could be confirmed by application of this new assay.
P E R S P E C T I V E S
The central theme of the studies presented in this thesis is directed at the possible
role of alterations in 11BHSD and cortisol metabolism in clinical conditions
characterizedby sodium and fluid retention or by changes in glucose homeostasis.
In brief, oLrr experiments do not support the contention that a diminished 11BHSD
activity contributes to sodium retention in proteinuric patients or cluring acute
administration of angiotensins. On the contrary, we found evictence for an
enhanced activity of 11BHSD type 2 in these conditions, which is expected to
diminish sodium retention. Although we were not able to demonstrate a direct
relationship between alterations in 11BHSD activity and glucose homeostasis in
either type 1 or type 2 diabetes mellitus, we did find that changes in cortisol
metabolism rnight represent a link between sodium status and insulin sensitivity
in healthy subjects. The next paragraphs wil l briefly cliscuss how future studies
could cleal with some questions raised by our studies, in particular with respect
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LIPHSD and the insulin resistance srlndrotne
The insulin resistance syndrome (synonyms: metabolic syndrome, syndrome X)
represents a cluster of interrelated cardiorrascular risk factors, with glucose
intolerance, hypertension, dyslipidemia and central obesity as its cardinal featuresl.
The exact pathophysiology of the insulin resistance syndrome still remains to be
elucidated. As already mentioned in chapter 6, our negative findings do not
preclude a contribution of 11BHSD to the insulin resistance syndrome, as tissue-
speci f ic  a l terat ions in 11BHSD act iv i ty cannot be accurately determined by
measurement of the commonly used urinary ratios of cortisol metabolites. Recent
studies have provided additional evidence for the pathophysiological role of
11BHSD in the metabolic syndrome. Animal as well as human experiments have
demonstrated that obesity is associated with tissue-specific alterations in 11PHSD
type 1 activity. For example, 11BHSD type 1 activity in obese Zucker rats is
reduced in liver but enhanced in adipose tissue 2. A similar distribution pattern
of 11pHSD type 1 activity has been found in humans 3, The potential significance
of 11BHSD in the pathophysiology of the insulin resistance syndrome has been
substantiated further by the demonstration that the metabolic syndrome could
be generated in transgónic mice selectively overexpressing 11BHSD type 1 in
adipose tissue to an extent similar to that found in adipose tissue from obese
humans a. Thus it can be envisaged that a selectively enhanced 11BHSD type 1
activity will promote visceral obesity through the increased local production of
glucocorticoids in visceral adipose tissue. This intriguing new pathophysiological
mechanism of insulin resistance obviously provides an opportunity to develop
specific therapies targeted at reduction of 11BHSD type 1 activity. Indeed, a recent
experiment showed the efficacy of a seiective inhibitor of mouse 11BHSD type 1,
BVT 2733. in lowering blood glucose levels in spontaneously hyperglycaemic
mice s. Moreover, it has been demonstrated that fenofibrate, a PPARcT agonist,
has the ability to downregulate murine hepatic 11BHSD type 1 activity 6. Although
hepatic 11BHSD type 1 activity seems to be decreased already in obese subjects, a
further reduction of its activity could still improve glucose tolerance. Perhaps
the previously observed improvement of insulin sensitivity during administration
of fenofibrate is partly explained by its inhibit ion of hepatic 11BHSD type 1 '/.
Thiazolidinediones, which are PPARy agonists, represent a new class of oral
hypoglycaemic agents. Despite their proven benefit, the precise mode of action
of thiazolidinediones is not completely understood. Interestingly, it has recently
been demonstrated that rosiglitazone, a PPARy agonist, carr downregulate the
activity of 11BHSD type 1 in adipose tissue E. Therefore, the therapeutic efficacy
of thiazolidinediones in the metabolic syndrome may at least in part be explained
by inhibit ion of 11BHSD type 1 in adipose tissue.
Future studies need to address the extent to which changes in 11BHSD activity
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IIPHSD and the insulin resistqnce syndrome
The insulin resistance syndrome (synonyms: metabolic syndrome, syndrome X)
represents a cluster of interrelated cardiovascular risk factors, with glucose
irrtolerance, hypertension, dyslipidemia and central obesity as its cardinal features r.
The exact pathophysiology of the instrlin resistance syndrome still remains to be
elucidated. As already mentioned in chapter 6, our ne€tative findings do not
preclude a contribution of 11BHSD to the insulin resistance syndrome, as tissue-
specific alterations in 11BHSD actirrity cannot be accurately determined by
measurement of the commonly used urinary ratios of cortisol metabolites. Recent
studies have provided additional evidence for the pathophysiological role of
11BHSD in the metabolic syndrome. Animal as well as human experiments have
demonstrated that obesity is associated with tissue-specific alterations in 11pHSD
type 1 activity. For example, 11BHSD type 1 activity in obese Zucker rats is
reduced in l iver but enhanced in adipose tissue 2. A similar distribution pattern
of 11BHSD type 1 activity has been found in humans 3. The potential significance
of 11PHSD in the pathophysiologv of the insulin resistance syndrome has been
substantiated further by the demonstration that the metabolic syndrome could
be generated in transgenic mice selectively overexpressing 11BHSD type 1 in
adipose tissue to an extent similar to that found in adipose tissue from obese
humans a. Thus it can be envisaged that a selectively enhanced 11BHSD type 1
activity will promote visceral obesity through the increased local production of
glucocorticoids in visceral adipose tissue. This intriguing new pathophysiological
mechanism of insulin resistance obviously provides an opportunity to develclp
specific therapies targeted at reduction of 11BHSD type 1 activity. Indeed, a recent
experiment showed the efficacy of a selective inhibitor of mouse 11BHSD type 1,
BVT 2733. in lowering blood glucose levels in spontaneously hyperglycaemic
mice s. Moreover, it has been demonstrated that fenofibrate, a PPARc ap;onist,
has the ability to downregulate murine hepatic 11BHSD type 1 activity 6. Although
hepatic 11BHSD type 1 activity seems to be decreased already in obese subjects, a
further reduction of its activity could still improve glucose tolerance. Perhaps
the previously observed improvement of insulin sensitivity during administration
of fenofibrate is partly explained by its inhibition of hepatic 11BHSD type 1 '/.
Thiazolidinediones, which are PPARy agonists, represent a new class of oral
hypoglycaemic agents. Despite their proven benefit, the precise mode of action
of thiazolidinediones is not completely understood. Interestingiy, it has recently
been demonstrated tl-rat rosiglitazone, a PPAR1 agonist, can downregulate the
activity of llBFISD type 1 in adipose tissue 8. Therefore, the therapeutic efficacy
of thiazolidinediones in the metabolic syndrome may at least in part be explained
by inhibit ion of 11BHSD type 1 in adipose tissue.
Future studies need to address the extent to which changes in 11pHSD activity
contribtrte to the insulin resistance svndrome. In additiorr, it is to be expected
131
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after 12 months rhGH the (THF + al lo-THF)/THE rat io decreased only in
cortisone acetate treated patients. The sum of urinary cortisol metabolites dicl
not change after rhCH in either group. The UFF /IJFE ratio tended to decrease
in cortisone acetate treated as weil as in patients with intact adrenal function.
Thus, it is suggested that 11BHSD type 1 activity is decreased by rhCH
replacement, which becomes manifest in patients receiving cortisone acetate
substitution therapy. 11pHSD type2activity is unaltered or may even be increased.
The bioavailabil ity of conventional doses cortisone acetate is unlikely to be
impaired by rhGH replacement in hypopituitary patients.
Chapter 8 descr ibes a new assay, based on gas chromatography and mass
spectrometry, to detect low concentrations of 1BB-glycyrrhetinic acid (1BBGA) in
urine, the hydrolytic product of glycyrrhizin. lBBGA inhibits the dehydrogenase
actir,'ity of 11BHSD, and is therefore responsible for the mineralocorticoid side-
effects of l iquorice.
The detection limit for 1BBGA of the gas chromatography assay was 10 Vg/\,
which was flrrther lowered to 3 1tg/l by subsequent mass spectrometry. The
performance of this newly developed assay is demonstrated in a group of four
volunteers corlsuming different amounts of liquorice. In addition, its clinical value
is i l lustrated in two patients with hypokalaemic hypertension and suppressed
plasma renin activity and aldosterone, in whom a suspicion of l iquorice abuse
could be confirmed by application of this new assay.
P E R S P E C T I V E S
The central theme of the studies presented in this thesis is dirc.cted at the possible
role of alterations in 11BHSD and cortisol metabolism in clinical conditions
characterizedby sodium and fluid retention or by changes in glucose homeostasis.
In brief, our experiments do not support the contention that a diminished 11BHSD
activity contributes to sodium retention in proteinuric patients or during acute
administration of angiotensins. On the contrary, we found evidence for an
enhanced activity of 11BHSD type 2 in these conditions, which is expected to
diminish sodium retention. Although we were not able to demonstrate a direct
relationship between alterations in 11BHSD activity and glucose homeostasis in
either type 1 or type 2 diabetes mellitus, we did find that changes in cortisol
metabolism might represent a link between sodium status and insulin sensitivity
in healthy subjects. The next paragraphs will briefly discuss how future studies
could deal with some questions raised by our studies, in particular with respect


































llpHSD and the insulin resistance syndronte
The insulin resistance syndrome (synonyms: metabolic syndrome, syndrome X)
represents a cluster of interrelated cardiovascular risk factors, with glucose
intolerance, hypertension, dyslipidemia and central obesity as its cardinal featuresl.
The exact pathophysiology of the insulin resistance syndrome still remains to be
elucidated. As already mentioned in chapter 6, our negative findings do not
preclude a contribution of 11BHSD to the insulin resistance syndrome, as tissue-
specific alterations in 11BHSD activity cannot be accurately determined by
measurement of the commonly used urinary ratios of cortisol metabolites. Recent
studies have provided additional evidence for the pathophysiological role of
11BHSD in the metabolic syndrome. Animal as well as human experiments have
demonstrated that obesity is associated with tissue-specific alterations in 11BHSD
type 1 activity. For example, 11BHSD type 1 activity in obese Zucker rats is
reduced in l iver but enhanced in adipose tissue 2. A similar distribution pattern
of 11BHSD type 1 activity has been found in humans 3. The potential significance
of 11BHSD in the pathophysiology of the insulin resistance syndrome has been
substantiated further by the demonstration that the metabolic syndrome could
be generated in transgónic mice selectively overexpressing tf $HSn type 1 in
adipose tissue to an extent similar to that found in adipose tissue from obese
humans a. Thus it can be envisaged that a selectively enhanced 11BHSD type 1
activity will promote visceral obesity through the increased local production of
glucocorticoids in visceral adipose tissue. This intriguing new pathophysiological
mechanism of insulin resistance obviously provides an opportunity to de'u'elop
specific therapies targeted at reduction of 11BHSD type 1 actir.ity. Indeed, a recent
experiment showed the efficacy of a selective inhibitor of mouse 11BHSD type 1,
BVT 2733. in lowering blood glucose levels in spontaneously hyperglycaernic
mice s. Moreover, it has been demonstrated that fenofibrate, a PPARu agonist,
has the ability to downregulate murine hepatic 11BHSD type 1 activity'i. Although
hepatic 11PHSD type 1 activity seems to be decreased already in obese subjects, a
further reduction of its activity could still improve glucc-rse tolerance. Perhaps
the previously observed improvement of insulin sensitivity durir-rg administration
of fenofibrate is partly explained by its inhibit ion of hepatic 11BHSD type 17.
Thiazolidinediones, which are PPARy agonists, represent a new class of oral
hypoglycaemic agents. Despite their proven benefit, the precise mode of action
of thiazolidinediones is not completely understood. Interestingly, it has recently
been demonstrated that rosiglitazone, a PPARy agonist, .o., ào*nregulate the
actir.ity of 11BHSD type 1 in adipose tissue *. Therefore, the therapeutic efficacy
of thiazolidinediones in the metabolic syndrome rnay at least in part be explained
bv inhibit ion of 11BHSD type 1 in adipose tissue.
Future studies need to address the extent to which changes in 11BHSD activity
contribute to the insulin resistance syndrome. In addition, it is to be expected
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that specific 11BHSD type 1 inhibitors wil l be developed, thus possibly providing
a ltew class of drugs for treatment of the insulin resistance syndrome.
Salt  sensi t iu i t r l  and cort isol  metabol ísm
The inverse relationship between changes in cortisol metabolite excretion and
blood pressure after salt loading in normotensive subjects, as described in chapter
4, has not been reported before. Our hypothesis that these changes depend on
sodium-induced alterations in cortisol elimination needs to be confirmed by
additional studies. For instance, the cortisol elimination rate could be assessed
after a lon,- and high-salt cl iet by determination of the plasma half-l i fe of labelled
cortisol. If our hypothesis is correct, then salt-resistant subjects would demonstrate
ar shortened half-life of plasma cortisol after salt loading, as a result of an increased
metabolic clearance. Alternatively, our hypothesis could be tested by continuous
cortisol aclministration to aclrenalectomized animals (e.9. Dahl salt-sensitive rats)
at different salt intakes. In this model, cortisol elimination rate can be assessed
indirectly as the amount of infused cortisol needed to stabil ize plasma cortisol.
Clearly, such a model has the advantage that compensatory activity of the HI']A-
axis is circurnvented. As pointed out in chapter 4, alterations in circulating cortisol
as well as in 11PHSD setpoint are unlikely to represent a major determinant of
salt sensitivitv. These changes in circulating cortisol might, however, be directly
involved in the sodium-induced alterations of insulin sensitivity. It should be
noted that this relationship was observed in a group of healthy, normotensive
individuals. It r.t,ould be of interest to know whether this relationship can also be
dernonstrated in hypertensive subjects, in whom salt sensitivity as r.t'ell as insulin
resistance are more prevalent than in normotensive subjects. Obr.iously, the
demonstration of a relationship between sodium-induced changes in circulating
cortisol levels and insulin sensitivity does not mean that these two phenomena
are also causally related. For proof of concept, it would be necessary to evaluate
w.hether insulin sensitivity also changes after salt loading if sodium-induced
alterations in plasma cortisol are prevented. This could, for instance, be achieved
in aclrenalectomized animals, with immediate adjustment of the sodium-induced
plasma cortisol alterations through a continuous infusion of cortisol.
Thus, future studies should be able to elucidate whether or not variation in
circulating cor"tisol evels represent a causal link between salt sensitivity and insulin
resistance.
11 PHSD and the renin- angiotensin- aldo sterone sy stem
It is suggested in chapter 2 that renal 11 PHSD type2 can be acutelv stimulatecl by
arrgiotensin-I and lI, as inferred frorn the observecl decrease in IJFF / UFE ratios
during their respective adrninistration. Additional studies are needed to confirm
this hypothesis. In vier.v of their widespread use, it l t,ould be irrteresting to know
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blockers wil l cause the opposite effect, i.c. inhibit ion of renal l lBIISD type 2,
which coulcl l imit the natriuretic response to these drugs. Although in chapter 3
rve did not observe an effect of losartan on parameters of 11pHSD activity, this
migl-rt have been due to the relatively low dose of this angiotensin-Il receptor
blocker that was adrnirristered. Therefore, additional dose-effect studies should
provide the answer whether these drugs inhibit renal 11PHSD type 2 or not. As
yet, no other agents than angiotensin have been identif ied to stimulate renal
11BHSD type 2. Future studies may characterize other substances with a similar
stimulating effect on renal 11PHSD type 2, thus potentially creating a new class
of natriuretic agents.
The physiological importance of 11BHSD in regulating the cortisol to cortisone
interconversion has been clearly dernonstrated. There' is gron,ing; evidence
establishing the role of 11BHSD in a number of clinical conditions. Thus, an altered
11BHSD activity has e.g also been implicated in neoplasia, osteoporosis, low birth
weight, glaucoma and cognitive dysfunction "-r3. Individual susceptibil i ty to the
consequences  o f  an  a l te red  11PHSD ac t iv i t y  migh t  be  in  par t  genet ica l l y
determined Ir. Data on the genomics of 11BHSD are still limited, but could augment
our insight into the effects of 11BHSD at the moiecular level in the near future. In
addition, it might generate useful information for designing drugs that wil l be
able to rnodulate selectively the activity of 11BHSD type 1 and type 2.
h-r conclusion, these many aspects of 11BHSD will continue to offer a relevant
field of research. Further studies will undoubtedly provide additional informatiorr
with irnportant consequences for daily clinicr-rl practice.
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